Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;66(7):e22540.
doi: 10.1002/dev.22540.

Attention Deficit Hyperactivity Disorder, Cannabis Use, and the Endocannabinoid System: A Scoping Review

Jennie E Ryan  1 , Mitchell Fruchtman  2 , Andrea Sparr-Jaswa  3 , Amy Knehans  4 , Brooke Worster  2
Affiliations

Attention Deficit Hyperactivity Disorder, Cannabis Use, and the Endocannabinoid System: A Scoping Review

Jennie E Ryan et al. Dev Psychobiol. 2024 Nov.

Abstract

There is emerging evidence that the endocannabinoid system (ECS) plays a significant role in the pathophysiology of many psychiatric disorders, including attention deficit hyperactivity disorder (ADHD). Increasing evidence suggests that a number of neurobiological correlates between endogenous cannabinoid function and cognitive dysfunction are seen in ADHD, making the ECS a possible target for therapeutic interventions. Cannabis use and cannabis use disorder are more prevalent in individuals with ADHD, compared to the general population, and there is growing popular perception that cannabis is therapeutic for ADHD. However, the relationship between cannabis use and ADHD symptomology is poorly understood. Further understanding of the role of the ECS in ADHD pathophysiology and the molecular alterations that may be a target for treatment is needed. To further the science on this emerging area of research, this scoping review describes the preclinical and clinical evidence seeking to understand the relationship between the ECS and ADHD.

Keywords: attention deficit hyperactivity disorder; cannabinoids; cannabis; endocannabinoid system.

PubMed Disclaimer

References

    1. Arnsten, A. F. 2009. “The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex.” Journal of Pediatrics 154, no. 5: I–S43. https://doi.org/10.1016/j.jpeds.2009.01.018.
    1. August, G. J., K. C. Winters, G. M. Realmuto, T. Fahnhorst, A. Botzet, and S. Lee. 2006. “Prospective Study of Adolescent Drug Use Among Community Samples of ADHD and Non‐ADHD Participants.” Journal of the American Academy of Child and Adolescent Psychiatry 45, no. 7: 824–832.
    1. Bastioli, G., J. C. Arnold, M. Mancini, et al. 2022. “Voluntary Exercise Boosts Striatal Dopamine Release: Evidence for the Necessary and Sufficient Role of BDNF.” Journal of Neuroscience 42, no. 23: 4725–4736. https://doi.org/10.1523/jneurosci.2273‐21.2022.
    1. Beninger, R. J., and T. J. Banasikowski. 2008. “Dopaminergic Mechanism of Reward‐Related Incentive Learning: Focus on the Dopamine D(3) Receptor.” Neurotoxicity Research 14: 57–69.
    1. Biederman, J., C. Petty, R. Fried, et al. 2007. “Stability of Executive Function Deficits Into Young Adult Years: A Prospective Longitudinal Follow‐Up Study of Grown Up Males With ADHD.” Acta Psychiatrica Scandinavica 116, no. 2: 129–136.

Publication types

MeSH terms

Substances

LinkOut - more resources